Isolating and expanding endothelial progenitor cells from peripheral blood on peptide-functionalized polystyrene surfaces.

endothelial progenitor cells ex vivo expansion extracellular matrix-derived peptides surface modification vascular regeneration xeno-free

Journal

Biotechnology and bioengineering
ISSN: 1097-0290
Titre abrégé: Biotechnol Bioeng
Pays: United States
ID NLM: 7502021

Informations de publication

Date de publication:
10 2019
Historique:
received: 25 04 2019
revised: 19 06 2019
accepted: 01 07 2019
pubmed: 10 7 2019
medline: 10 9 2020
entrez: 10 7 2019
Statut: ppublish

Résumé

The expansion of human peripheral blood endothelial progenitor cells to obtain therapeutically relevant endothelial colony-forming cells (ECFCs) has been commonly performed on xeno-derived extracellular matrix proteins. For cellular therapy applications, xeno-free culture conditions are desirable to improve product safety and reduce process variability. We have previously described a novel fluorophore-tagged RGD peptide (RGD-TAMRA) that enhanced the adhesion of mature endothelial cells in vitro. To investigate whether this peptide can replace animal-derived extracellular matrix proteins in the isolation and expansion of ECFCs, peripheral blood mononuclear cells from 22 healthy adult donors were seeded on RGD-TAMRA-modified polystyrene culture surfaces. Endothelial colony formation was significantly enhanced on RGD-TAMRA-modified surfaces compared to the unmodified control. No phenotypic differences were detected between ECFCs obtained on RGD-TAMRA compared to ECFCs obtained on rat-tail collagen-coated surfaces. Compared with collagen-coated surfaces and unmodified surfaces, RGD-TAMRA surfaces promoted ECFC adhesion, cell spreading, and clonal expansion. This study presents a platform that allows for a comprehensive in vitro evaluation of peptide-based biofunctionalization as a promising avenue for ex vivo ECFC expansion.

Identifiants

pubmed: 31286475
doi: 10.1002/bit.27107
doi:

Substances chimiques

Oligopeptides 0
Polystyrenes 0
arginyl-glycyl-aspartyl-alanine 93674-98-7

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2598-2609

Subventions

Organisme : CIHR
ID : MOP 142285
Pays : Canada

Informations de copyright

© 2019 Wiley Periodicals, Inc.

Auteurs

Mohamed A Elkhodiry (MA)

Department of Chemical Engineering, McGill University, Montréal, Quebec, Canada.

Mariève D Boulanger (MD)

Department of Chemical Engineering, McGill University, Montréal, Quebec, Canada.

Omar Bashth (O)

Department of Chemical Engineering, McGill University, Montréal, Quebec, Canada.

Jean-François Tanguay (JF)

Coronary Care Unit, Montréal Heart Institute, Montréal, Quebec, Canada.
Department of Medicine, Université de Montréal, Montréal, Quebec, Canada.

Gaétan Laroche (G)

Département de Génie des Mines, des Matériaux et de la Métallurgie, Centre de Recherche du CHU de Québec, Université Laval, Quebec City, Quebec, Canada.

Corinne A Hoesli (CA)

Department of Chemical Engineering, McGill University, Montréal, Quebec, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH